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Abstract
p53 is a central tumor suppressor protein and its inhibition is believed to be a prerequisite for cancer development. In
approximately 50% of all malignancies this is achieved by inactivating mutations in the p53 gene. However, in several
cancer entities, including melanoma, p53 mutations are rare. It has been recently proposed that tyrosinase related protein 2
(TRP2), a protein involved in melanin synthesis, may act as suppressor of the p53 pathway in melanoma. To scrutinize this
notion we analyzed p53 and TRP2 expression by immunohistochemistry in 172 melanoma tissues and did not find any
correlation. Furthermore, we applied three different TRP2 shRNAs to five melanoma cell lines and could not observe a target
specific effect of the TRP2 knockdown on either p53 expression nor p53 reporter gene activity. Likewise, ectopic expression
of TRP2 in a TRP2 negative melanoma cell line had no impact on p53 expression. In conclusion our data suggest that p53
repression critically controlled by TRP2 is not a general event in melanoma.
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Introduction
Advanced melanoma is a cancer that is largely resistant to
cytotoxic drugs or irradiation; this had been at least in part
attributed to an impaired p53 dependent apoptosis response
[1]. The main biological functions of the transcription factor
p53 include regulation of cell cycle progression, apoptosis,
senescence, cellular differentiation and DNA repair [2]. Due to
fast ubiquitination by the E3 ligase MDM2 and subsequent
proteasomal degradation, p53 is frequently undetectable in
normal cells [3]. However, upon several different stresses,
including oncogenic stress or DNA damage, the amount of p53
is increased due to disruption of its degradation [4,5]. p53 is a
prototypic tumor suppressor and inactivating mutations in the
p53 gene are present in approximately half of all human
cancers [2]. Alternative mechanisms of p53 inactivation
include MDM2/4 overexpression [3,4], inhibition by viral
oncoproteins [5] and loss of p14ARF, which binds MDM2 and
inhibits its E3 ubiquitin ligase activity [3]. In addition, the
transcriptional activity of p53 can also be impaired on a post-
translational level by competition for DNA-binding sites by the
p73 isoform DNp73 [6,7], functional antagonism with the
inhibitor of apoptosis-stimulating protein (iASPP) [6,8] and
sequestration in the cytosol by the ubiquitin ligase Parc [9].
Moreover, inhibition of p53 expression by tyrosine-related
protein 2 (TRP2) has been proposed as a mechanism of p53
restriction [10]. Importantly, all of the aforementioned p53
inactivation mechanisms except inhibition by viral oncopro-
teins have been described in melanoma cells. This is of
particular interest since p53 is frequently expressed in
melanoma but inactivating mutations are rarely detectable [11–
14]. Interestingly, the putative negative p53 regulator TRP2 is a
marker of the melanocytic lineage and is expressed in more than
80% of metastatic melanoma lesions [15]. TRP2 is transcriptionally
regulated by microphthalmia transcription factor (MITF) and
Sox10. TRP2 acts in the melanin synthesis pathway downstream of
tyrosinase catalysing the conversion of dopachrome to 5,5-
dihydroxyindole-2-carboxylic acid (DHICA) [16–18]. Beside its
function in melanin synthesis TRP2 has been proposed to regulate
neural progenitor cell proliferation and to function as a pro-survival
and anti-apoptotic molecule [19]. In melanoma cell lines an
impaired apoptotic response after radiation or treatment with
chemotherapeutic agents was found to be associated with increased
expression of TRP2 [20]. A possible mechanistic explanation for the
anti-apoptotic property of TRP2 has recently been described [10].
Sendoel and co-workers showed in Caenorhabditis elegans that
secretion of the TRP2 homolog Tyr2 by sensory neurons inhibits
p53 expression of germ cells. Moreover, TRP2 knockdown in
WM266-4 melanoma cells lead to increased p53 expression
sensitizing the cells to cisplatin-induced apoptosis.
In this report we further scrutinize a possible role of TRP2 in
the regulation of p53 in five different melanoma cell lines and do
not find such a relation.
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Materials and Methods
Ethics Statement
Tumor samples from primary and metastatic melanomas were
obtained by surgical excision for either therapeutic or diagnostic
purposes and had undergone routine histology. The Institutional
Review Board of Wu¨rzburg University Hospital approved all
described studies and waived the need for written consent for
histochemical analysis of anonymised tumor samples. Generation
of the WueMel 45 melanoma cell line was done after written
consent from the patient (Ethikkommission der Medizinischen
Fakulta¨t der Universita¨t Wu¨rzburg; sequential study number 169/
12).
Tumor material and Tissue microarray (TMA)
After anonymization of tissue samples a dermatohistopatholo-
gist (C.K.) reviewed slides from all blocks, selecting representative
areas of tumor tissue to be cored for generation of TMA as
previously described [21]. The TMA used in this study contained
152 unique cases of primary melanoma (n= 129), and metastatic
melanoma (n= 23). Additionally, 20 melanoma tissues (10 primary
and 10 metastatic melanoma) for which a p53 wild type status had
been confirmed by sequencing of the exon 5–8 were included in
these studies.
Immunohistochemistry (IHC)
4 mm sections of paraffin-embedded tumors and TMA were
dried at 56uC and then treated twice with xylene for 10 min at
room temperature. Subsequently, sections were washed twice with
absolute ethanol and twice with 70% ethanol followed by one rinse
with bi-distilled water. For antigen retrieval, sections were
incubated with citrate buffer pH 9.0 (DAKO, Hamburg, Ger-
many) for 10 min at 90uC and rinsed with bi-distilled water. Next,
slides were rinsed twice with phosphate-buffered saline (PBS) and
thereafter incubated with Blocking Solution (DAKO, S2023) for
10 min at room temperature. After two additional washing steps
with PBS for 10 min at room temperature, the monoclonal a-p53
antibody (DO-7, DAKO) or a-TRP2 antibody (D18, Santa Cruz)
was added to the sections at a predetermined concentration in
PBS, followed by an over night incubation at 4uC. After two
10 min washes in PBS, biotinylated multispecies-specific second-
ary antibody (DAKO, K5003) was added to the sections for
30 min at room temperature. Slides were then washed twice in
PBS/bovine serum albumin, and bound antibodies were visualized
using streptavidin-HRP (DAKO K5003) and Vector Vip (Vector
Laboratories, Burlingame USA) as peroxidase substrate according
to the manufacturer’s guidelines. Finally, the nuclei were stained
with hemalaun.
Scoring of Immunohistochemistry staining results
The cores of specimens on the tissue microarray (TMA) slides
were scored using a semi-quantitative scoring system where
staining intensity and the proportion of stained tumor cells is
taken into account [7–18]. Every tumor was given a score
according to the intensity of staining (no staining = 0, weak
staining = 1, moderate staining = 2, strong staining = 3) and the
extent of stained cells (up to 10%=1, 11–50%=2, 51–80%=3,
81–100%=4). The final histology score was determined by
multiplying the intensity scores with the extent of positivity scores
of stained cells, yielding scores of 0, 1, 2, 3, 4, 6, 8, 9 or 12. Scoring
of the samples was performed by two independent individuals.
Statistical analysis
The relationship between the p53 and TRP2 expression was
statistically analyzed using the Prism Graph software 5.0 (San
Diego, CA). The coefficient of determination (R2) and the p value
were determined applying linear regression analysis comparing
p53 and TRP2 histology scores.
Cell culture
One melanoma cell line (WueMel45) was generated in our lab
from a melanoma metastasis obtained from a patient for
therapeutic purposes. This cell line as well as the melanoma cell
lines FM88 [22], MelU [23], MelJuso [24] and M26 [25] were
grown in RPMI 1640 supplemented with 10% fetal calf serum.
For all five cell lines all coding exons of the p53 gene were
sequenced demonstrating p53 wild type status [13].
Cloning
The shRNA vectors TRP2_shRNA #1, #2 and #3 were
obtained by cloning the shRNA sequences 59-GTGATTCAAA-
CAACTAACAGATCAAGAGTCTGTTAGTTGTTTGAATC-
ACATTTTTTT-39, 59-AAGGTTGGCAATTTCATGCTGTT-
CAAGAGACAGCATGAAATTGCCAACCTTTTTTTTT-39
and 59-CCACCAGTGATTCGGCAGATCAAGAGTCTGCC-
GAATCACTGGTGGTTTTTTT-39, respectively (the sense
strand is given), into the lentiviral vector KH1 [26]. A Scr shRNA
construct was used as a control [27]. A TRP2 cDNA was amplified
by PCR and inserted into the retroviral expression vector pIH [28].
To make the TRP2 mRNA insensitive to the TRP2_shRNA #2
(TRP2in) six silent mutations (59- ACAGCATGAAGCTGCC-
CACG-39; exchanged nucleotides displayed in bold) were intro-
duced in the shRNA target sequence using the quick change
mutagenesis kit (Stratagene, Waldbrunn, Germany).
Lentiviral and retroviral infection
Infectious viruses were raised by transfecting HEK293T cells
[29]. The lentiviral shRNA vectors and the pGreenFire p53
reporter construct (SBI, Mountain View, Canada) were transfect-
ed in combination with the helper constructs p59, p60 and p61.
The retroviral vector pIH-TRP2insens was transfected in combi-
nation with the helper constructs pHIT60 and pHIT456. Two
days following transfection, virus supernatants were harvested and
filtered through 0.45 mm pore size filters. For infection, virus-
containing supernatants were supplemented with 4 mg/ml poly-
brene and then added to the target cells overnight. Then medium
was changed and the cells were cultured for 3 more days prior to
subjecting lysates of the cells to further analysis. Pure populations
carrying the pGreenFire reporter were selected by culturing the
cells in the presence of puromycin.
p53 reporter gene assay
The p53 reporter construct pGreenFire lentiviral vector codes
for a puromycin resistence and for green fluorescent protein (GFP)
under the control of a p53 responsive element (46 CGA-
CATGCCCGGGCATGT). Following puromycin selection flow
cytometry to monitor GFP expression in pGreenFire transduced
cells was performed on a FACSCanto (BD, Heidelberg, Germany).
Mean GFP fluorescence intensities were normalized to the relative
presence of the reporter constructs in the infected cells as
determined by real time PCR [13].
Western blot
Cells were lysed in Laemmli buffer and proteins were resolved
by SDS-polyacrylamid gel electrophoresis and transferred to
p53 and TRP2 in Melanoma
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nitrocellulose membranes. Following blocking for 1 h with PBS
containing 0.05% Tween 20 and 5% powdered skim milk, blots
were incubated overnight with the primary antibody, washed three
times with PBS with 0.05% Tween 20, and then incubated with a
peroxidase coupled secondary antibody. Following extensive
washing, the bands were detected using a chemoluminescence
detection kit (Roche Diagnostics, Mannheim, Germany). Anti-
bodies to p53 (D-01, Santa Cruz, Heidelberg, Germany) TRP2
(D18, Santa Cruz, Heidelberg, Germany) and b-tubulin (Sigma,
Ottobrunn, Germany) were used.
Results
TRP2 and p53 co-expression in melanoma
Prompted by a report demonstrating an inhibitory effect of
TRP2 on p53 in a melanoma cell line [10] we examined the
expression of both proteins in a large panel of 172 paraffin
embedded primary and metastatic melanoma samples by IHC.
For this study we utilized a tumor tissue microarray of 129 primary
and 23 metastatic melanomas. In addition a series of consecutive
formalin-fixed, paraffin-embedded sections of human primary
(n = 10) and metastatic melanoma (n= 10) were included where
p53 mutational status was determined by nested PCR amplifica-
tion and direct sequencing of exons 5–8 which harbor 95% of the
known p53 mutations [13]. In line with previous reports no p53
mutations could be detected (data not shown) [13,30].
Overall p53 expression was detectable (score $1) in 99 out of
139 (71,2%) cases of primary melanoma and in 17 out of 33
(51,5%) cases of metastatic melanoma (Figure 1). p53 immuno-
reaction showed consistent prominent nuclear and light cytoplas-
mic staining pattern in all samples. TRP2 was detected in 119 out
of 139 (85%) cases of primary melanoma and 26 out of 33 (78%)
cases of metastatic melanoma displaying nuclear and cytoplasmic
staining. To compare p53 and TRP2 expression a semi-
quantitative immunoreactive score was determined by multiplying
the percentage of positive cells (P) with the average staining
intensity (I) using the formula Q=P x I [31,32] (Figure 1C).
Statistical regression analysis did not reveal any negative
correlation between TRP2 and p53 expression (Figure 1B). Quite
the contrary, a very poorly fitting coefficient of determination
(R2= 0,0258) and only borderline-significant (p = 0,352) positive
correlation was observed. Moreover, of all 52 samples with very
weak or no TRP2 staining (histology score of 0 or 1) 17 (33%) also
displayed very weak or negative p53 staining (histology score of 0
or 1). On the other hand of all 120 samples with middle to strong
TRP2 staining (histology score of 2–12) 44 (37%) displayed very
weak or negative p53 staining (histology score of 0 or 1). Taken
together these analyses reveal, that p53 expression is independent
of the TRP2 expression level. Moreover, both proteins are
detectable in the majority of samples and therefore expression is
not mutually exclusive.
TRP2 knockdown does not impact on p53 expression
To further scrutinize a possible role of TRP2 in the regulation of
p53 we performed a series of TRP2 knockdown experiments
addressing the expression and transcriptional activity of p53.
Initially, we analyzed the expression of p53 and TRP2 in the
melanoma cell lines FM88, M26, MelU, MelJuso, and WueMel45.
p53 was present in all five melanoma lines, whereas TRP2
expression was detected by western blot in all cell lines except
WueMel45. Three short hairpin RNAs were engineered to
suppress TRP2 expression. The efficacy of TRP2 knockdown
was confirmed by immunoblot; all three shRNAs strongly reduced
TRP2 protein expression in melanoma cell lines and the
knockdown was most prominent for TRP2-shRNA_#2
(Figure 2). To this end, even the most efficient TRP2 knockdown
had no effect on p53 expression levels as determined by western
blot (Figure 2).
To test whether the transcriptional activity of p53 may be
altered by TRP2 knockdown, the set of melanoma lines were
stably transduced with a reporter gene construct (pGreenFire)
coding for GFP under the control of a p53 response element. The
mean GFP expression was measured by flow cytometry and
normalized for the relative number of incorporated pGreenFire
copies as determined by real time PCR. As we have shown
previously expression levels of p53 do not necessarily correlate
with its transcriptional activity suggesting posttranslational inac-
tivation of p53 [13] which has recently been shown to occur in
melanoma e.g. by iASPP [8]. Accordingly, the M26 and WueMel
melanoma cell lines show high p53 expression (Figure 2A) without
any p53 reporter gene activity (Figure 3).
Interestingly, TRP2 knockdown by two of the three shRNAs
(#1 and #3) showed no impact on p53 reporter gene activity.
However, infection with the TRP2-shRNA_#2 led to increased
p53 reporter gene activity in FM88, Mel-U and MelJuso but not in
M26 and WueMel 45 melanoma cells (Figure 3). Therefore, the
results obtained with TRP2-shRNA_#1 and #3 suggest that
TRP2 does not play a role in the regulation of p53 while induction
of p53 reporter gene activity upon infection with the most effective
TRP2-shRNA_#2 in some of the cells would be consistent with an
inhibitory function of TRP2 in the p53 pathway. However,
shRNAs notoriously exert off target effects [33]. To evaluate
whether this is the case for TRP2-shRNA_#2 we investigated
whether the observed p53 activation can be rescued by re-
expression of TRP2. For this experiment we generated a modified
TRP2 expression construct coding for an TRP2 mRNA in which
the shRNA-binding site is modified by six silent mutations
(TRP2in). When TRP2-shRNA_#2 was expressed no downreg-
ulation of TRP2 was observed in cells stably expressing the
TRP2in construct thus, confirming the insensitivity of the ectopic
TRP2in mRNA (Figure 4) to TRP2-shRNA_#2. Subsequent
analysis of p53 transcriptional activity revealed that expression of
this shRNA insensitive TRP2in could not revert the increase in
p53 reporter gene activity in the presence of shRNA#2, indicating
that this is only an off target effect. Moreover, ectopic expression of
TRP2 in TRP2-negative WueMel45 melanoma cell line did not
repress p53 expression or transcriptional activity as it would be
expected when TRP2 functions as negative regulator in the p53
pathway (Figure 4).
Discussion
Inactivation or at least partial repression of the p53 tumor
suppressor pathway is thought to occur in almost all human
cancers, and inactivating p53 mutations are the genetic
alterations most frequently observed in malignancies [34,35].
However, in several cancer entities, including melanoma p53
mutations are rare [36]. In these cancers with suppressed wild
type p53 function, restoration of p53 activity is regarded as an
attractive therapeutic strategy [35,36]. However, for the devel-
opment of such therapeutic approaches we need to understand
the molecular mechanisms restricting p53 function in p53 wild
type tumors. The great interest in such mechanisms in melanoma
is reflected by several high impact publications during the last 12
months. Lu and co-workers, for example, demonstrated that in
melanoma a cyclin B1/cdk1 protein complex phosphorylates
iASPP leading to the inhibition of iASPP dimerization, increased
p53 and TRP2 in Melanoma
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nuclear entry of iASPP monomers, as well as binding and
inhibition of p53 [8]. Gembarska and colleagues demonstrated
that increased protein levels of the p53 inhibitor MDMX are
frequently found in melanomas rendering the p53 tumor
suppressor inactive [4]. A similar mechanism has previously
been described for MDM2 [4,37,38]. Moreover, p53 function
Figure 1. TRP2 and p53 expression in melanoma tissue. (A) Representative immunohistochemical staining for TRP2 and p53 in consecutive
sections of a primary melanoma; scale bars: upper panel 1 mm, lower panel 100 mm. (B) Linear regression analysis of p53 and TRP2 histology scores
derived from the analysis of 172 melanomas (139 primary and 33 metastatic melanoma) evaluated by a histopathologist. Staining intensity was
scored between 0 and 3 and the extent of positivity between 0 and 4. By multiplying both values a minimum score of 0 and a maximum of 12 was
derived; linear regression analysis comparing p53 and TRP2 histology scores revealed borderline-significant (p = 0,352) positive correlation and a
coefficient of determination (R2) of 0,0258. (C) Since the number of individual dots in B cannot be visualized the distribution of individual p53 and
TRP2 histology scores are displayed in the table.
doi:10.1371/journal.pone.0087440.g001
Figure 2. Knockdown of TRP2 by shRNA does not affect p53 expression level. (A) TRP2 and p53 expression in indicated melanoma cell lines
was determined by western blot. Tubulin was used as a loading control. (B) The indicated melanoma cell lines were transduced with three different
lentiviral TRP2 shRNAs (TRP2_#1, #2, #3) and on day four after shRNA infection the efficiency of the knockdown and p53 expression were analyzed
by immunoblotting; a scrambled (scr) shRNA was used as a control.
doi:10.1371/journal.pone.0087440.g002
p53 and TRP2 in Melanoma
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can be suppressed in melanoma due to expression of other p53
family members, including p63 and the N-terminal truncated
isoforms DNp73 which both act dominant-negative via hetero-
dimerization [6,7,39]. Most recently, a synonymous mutation in
the BCL2L12 gene was identified in melanoma leading to
increased expression of BCL2L12 which binds to p53 and inhibits
its transcriptional activity [40].
In our study we investigated the role of the TRP2 in p53
regulation prompted by a report of Sendoel and colleagues who
identified in Caenorhabditis elegans the TRP2 homolog TYR2 as a
protein secreted by neurons and acting paracrine in neighboring
germ cells to suppress CEP-1 (p53 homolog in the worm)
dependent apoptosis [10]. Using the melanoma cell line
WM266-4 which has been established from a lymph node
metastasis [41,42] they demonstrated that such a mechanism is
evolutionarily conserved. In this respect they demonstrate that a
TRP2 shRNA leads to upregulation of p53 protein levels and that
the shRNA mediated TRP2 knockdown increased cisplatin
induced apoptosis in the melanoma cell line [10]. To scrutinize
to which extent TRP2 is restricting p53 expression and/or p53
Figure 3. Effects of TRP2 inhibition by shRNA on transcriptional activity of p53. Indicated melanoma cell lines were stably transduced with
a lentiviral pGreenFire reporter construct encoding for green fluorescence protein (GFP) under the control of a p53 responsive element (46
CGACATGCCCGGGCATGT). The cells were then infected with the different lentiviral supernatants carrying the shRNA expression construct KH1
containing either a scrambled or a sequence targeting TRP2. Mean GFP activity four days post infection is depicted, normalized to the relative vector
load of the cell lines determined by Real time PCR.
doi:10.1371/journal.pone.0087440.g003
Figure 4. Ectopic re-expression of TRP2 does not rescue the p53 activation induced by TRP2-shRNA_#2. Indicated melanoma cell lines
were stably transduced with a lentiviral p53 reporter construct and a modified TRP2 expression construct coding for TRP2 mRNAs in which the
shRNA-binding site is modified by six silent mutations (TRP2in). On day 4 following infection total cell lysates were analyzed for TRP2 and p53
expression by immunoblotting (lower part) with tubulin used as a loading control. In the upper part the corresponding mean GFP fluorescence
intensity is depicted, normalized to the relative reporter vector load of the cell lines determined by real time PCR.
doi:10.1371/journal.pone.0087440.g004
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function in melanoma we analyzed a large set of melanoma tissues
as well as five melanoma cell lines. However, immunohistochem-
ical analysis of the 172 melanoma lesions did not reveal any
correlation between TRP2 and p53 expression, arguing against a
critical dependency. Furthermore, neither efficient TRP2 knock-
down in TRP2-positive melanoma cells using three different
shRNAs caused a target specific increase in p53 function nor did
overexpression of TRP2 in a TRP2 negative melanoma cell line
repress p53 expression. The discrepancy between our data and the
one reported by Sendoel et al. could be due to the fact that
different cell lines were used in the two studies. Therefore, we
cannot exclude that the inhibitory effect of TRP2 on p53
described by Sendoel et al. is a cell line specific phenomenon. It
is also known that different cell culture practices and cell culture
conditions used in different laboratories can have a major
influence on gene expression and consequently can lead to
different experimental results [43,44]. Our data from cell culture
experiments, however, are not only consistent between different
cell lines and different shRNAs, but the conclusion derived from
these experiments is also in line with our immunohistochemical
studies. In summary our results suggest that TRP2 is not generally
suppressing p53 in melanoma and that with respect to future
therapeutic strategies the aforementioned proteins i.e. iASPP, p63
and MDMX appear to be more promising targets.
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